Teva presents new long-term austedo® (deutetrabenazine) tablets data at 2022 american psychiatric association annual meeting

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced new efficacy and safety data from a 3-year open-label extension (ole) study on austedo® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (td). these data will be presented at the 2022 american psychiatric association (apa) annual meeting, held may 21-25 in new orleans and online june 7-10. in addition
TEVA Ratings Summary
TEVA Quant Ranking